Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the r...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) Jg. 399; H. 10332; S. 1303 - 1312 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
02.04.2022
Elsevier Limited Elsevier |
| Schlagworte: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.
Individual-level data on laboratory-confirmed COVID-19 cases resident in England between Nov 29, 2021, and Jan 9, 2022, were linked to routine datasets on vaccination status, hospital attendance and admission, and mortality. The relative risk of hospital attendance or admission within 14 days, or death within 28 days after confirmed infection, was estimated using proportional hazards regression. Analyses were stratified by test date, 10-year age band, ethnicity, residential region, and vaccination status, and were further adjusted for sex, index of multiple deprivation decile, evidence of a previous infection, and year of age within each age band. A secondary analysis estimated variant-specific and vaccine-specific vaccine effectiveness and the intrinsic relative severity of omicron infection compared with delta (ie, the relative risk in unvaccinated cases).
The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0·56 (95% CI 0·54–0·58); for hospital admission and death, HR estimates were 0·41 (0·39–0·43) and 0·31 (0·26–0·37), respectively. Omicron versus delta HR estimates varied with age for all endpoints examined. The adjusted HR for hospital admission was 1·10 (0·85–1·42) in those younger than 10 years, decreasing to 0·25 (0·21–0·30) in 60–69-year-olds, and then increasing to 0·47 (0·40–0·56) in those aged at least 80 years. For both variants, past infection gave some protection against death both in vaccinated (HR 0·47 [0·32–0·68]) and unvaccinated (0·18 [0·06–0·57]) cases. In vaccinated cases, past infection offered no additional protection against hospital admission beyond that provided by vaccination (HR 0·96 [0·88–1·04]); however, for unvaccinated cases, past infection gave moderate protection (HR 0·55 [0·48–0·63]). Omicron versus delta HR estimates were lower for hospital admission (0·30 [0·28–0·32]) in unvaccinated cases than the corresponding HR estimated for all cases in the primary analysis. Booster vaccination with an mRNA vaccine was highly protective against hospitalisation and death in omicron cases (HR for hospital admission 8–11 weeks post-booster vs unvaccinated: 0·22 [0·20–0·24]), with the protection afforded after a booster not being affected by the vaccine used for doses 1 and 2.
The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks is a larger reduction in intrinsic severity (in unvaccinated individuals) counterbalanced by a reduction in vaccine effectiveness. Documented previous SARS-CoV-2 infection offered some protection against hospitalisation and high protection against death in unvaccinated individuals, but only offered additional protection in vaccinated individuals for the death endpoint. Booster vaccination with mRNA vaccines maintains over 70% protection against hospitalisation and death in breakthrough confirmed omicron infections.
Medical Research Council, UK Research and Innovation, Department of Health and Social Care, National Institute for Health Research, Community Jameel, and Engineering and Physical Sciences Research Council. |
|---|---|
| AbstractList | The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.
Individual-level data on laboratory-confirmed COVID-19 cases resident in England between Nov 29, 2021, and Jan 9, 2022, were linked to routine datasets on vaccination status, hospital attendance and admission, and mortality. The relative risk of hospital attendance or admission within 14 days, or death within 28 days after confirmed infection, was estimated using proportional hazards regression. Analyses were stratified by test date, 10-year age band, ethnicity, residential region, and vaccination status, and were further adjusted for sex, index of multiple deprivation decile, evidence of a previous infection, and year of age within each age band. A secondary analysis estimated variant-specific and vaccine-specific vaccine effectiveness and the intrinsic relative severity of omicron infection compared with delta (ie, the relative risk in unvaccinated cases).
The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0·56 (95% CI 0·54-0·58); for hospital admission and death, HR estimates were 0·41 (0·39-0·43) and 0·31 (0·26-0·37), respectively. Omicron versus delta HR estimates varied with age for all endpoints examined. The adjusted HR for hospital admission was 1·10 (0·85-1·42) in those younger than 10 years, decreasing to 0·25 (0·21-0·30) in 60-69-year-olds, and then increasing to 0·47 (0·40-0·56) in those aged at least 80 years. For both variants, past infection gave some protection against death both in vaccinated (HR 0·47 [0·32-0·68]) and unvaccinated (0·18 [0·06-0·57]) cases. In vaccinated cases, past infection offered no additional protection against hospital admission beyond that provided by vaccination (HR 0·96 [0·88-1·04]); however, for unvaccinated cases, past infection gave moderate protection (HR 0·55 [0·48-0·63]). Omicron versus delta HR estimates were lower for hospital admission (0·30 [0·28-0·32]) in unvaccinated cases than the corresponding HR estimated for all cases in the primary analysis. Booster vaccination with an mRNA vaccine was highly protective against hospitalisation and death in omicron cases (HR for hospital admission 8-11 weeks post-booster vs unvaccinated: 0·22 [0·20-0·24]), with the protection afforded after a booster not being affected by the vaccine used for doses 1 and 2.
The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks is a larger reduction in intrinsic severity (in unvaccinated individuals) counterbalanced by a reduction in vaccine effectiveness. Documented previous SARS-CoV-2 infection offered some protection against hospitalisation and high protection against death in unvaccinated individuals, but only offered additional protection in vaccinated individuals for the death endpoint. Booster vaccination with mRNA vaccines maintains over 70% protection against hospitalisation and death in breakthrough confirmed omicron infections.
Medical Research Council, UK Research and Innovation, Department of Health and Social Care, National Institute for Health Research, Community Jameel, and Engineering and Physical Sciences Research Council. Summary Background The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort. Methods Individual-level data on laboratory-confirmed COVID-19 cases resident in England between Nov 29, 2021, and Jan 9, 2022, were linked to routine datasets on vaccination status, hospital attendance and admission, and mortality. The relative risk of hospital attendance or admission within 14 days, or death within 28 days after confirmed infection, was estimated using proportional hazards regression. Analyses were stratified by test date, 10-year age band, ethnicity, residential region, and vaccination status, and were further adjusted for sex, index of multiple deprivation decile, evidence of a previous infection, and year of age within each age band. A secondary analysis estimated variant-specific and vaccine-specific vaccine effectiveness and the intrinsic relative severity of omicron infection compared with delta (ie, the relative risk in unvaccinated cases). Findings The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0·56 (95% CI 0·54–0·58); for hospital admission and death, HR estimates were 0·41 (0·39–0·43) and 0·31 (0·26–0·37), respectively. Omicron versus delta HR estimates varied with age for all endpoints examined. The adjusted HR for hospital admission was 1·10 (0·85–1·42) in those younger than 10 years, decreasing to 0·25 (0·21–0·30) in 60–69-year-olds, and then increasing to 0·47 (0·40–0·56) in those aged at least 80 years. For both variants, past infection gave some protection against death both in vaccinated (HR 0·47 [0·32–0·68]) and unvaccinated (0·18 [0·06–0·57]) cases. In vaccinated cases, past infection offered no additional protection against hospital admission beyond that provided by vaccination (HR 0·96 [0·88–1·04]); however, for unvaccinated cases, past infection gave moderate protection (HR 0·55 [0·48–0·63]). Omicron versus delta HR estimates were lower for hospital admission (0·30 [0·28–0·32]) in unvaccinated cases than the corresponding HR estimated for all cases in the primary analysis. Booster vaccination with an mRNA vaccine was highly protective against hospitalisation and death in omicron cases (HR for hospital admission 8–11 weeks post-booster vs unvaccinated: 0·22 [0·20–0·24]), with the protection afforded after a booster not being affected by the vaccine used for doses 1 and 2. Interpretation The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks is a larger reduction in intrinsic severity (in unvaccinated individuals) counterbalanced by a reduction in vaccine effectiveness. Documented previous SARS-CoV-2 infection offered some protection against hospitalisation and high protection against death in unvaccinated individuals, but only offered additional protection in vaccinated individuals for the death endpoint. Booster vaccination with mRNA vaccines maintains over 70% protection against hospitalisation and death in breakthrough confirmed omicron infections. Funding Medical Research Council, UK Research and Innovation, Department of Health and Social Care, National Institute for Health Research, Community Jameel, and Engineering and Physical Sciences Research Council. The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.BACKGROUNDThe omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.Individual-level data on laboratory-confirmed COVID-19 cases resident in England between Nov 29, 2021, and Jan 9, 2022, were linked to routine datasets on vaccination status, hospital attendance and admission, and mortality. The relative risk of hospital attendance or admission within 14 days, or death within 28 days after confirmed infection, was estimated using proportional hazards regression. Analyses were stratified by test date, 10-year age band, ethnicity, residential region, and vaccination status, and were further adjusted for sex, index of multiple deprivation decile, evidence of a previous infection, and year of age within each age band. A secondary analysis estimated variant-specific and vaccine-specific vaccine effectiveness and the intrinsic relative severity of omicron infection compared with delta (ie, the relative risk in unvaccinated cases).METHODSIndividual-level data on laboratory-confirmed COVID-19 cases resident in England between Nov 29, 2021, and Jan 9, 2022, were linked to routine datasets on vaccination status, hospital attendance and admission, and mortality. The relative risk of hospital attendance or admission within 14 days, or death within 28 days after confirmed infection, was estimated using proportional hazards regression. Analyses were stratified by test date, 10-year age band, ethnicity, residential region, and vaccination status, and were further adjusted for sex, index of multiple deprivation decile, evidence of a previous infection, and year of age within each age band. A secondary analysis estimated variant-specific and vaccine-specific vaccine effectiveness and the intrinsic relative severity of omicron infection compared with delta (ie, the relative risk in unvaccinated cases).The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0·56 (95% CI 0·54-0·58); for hospital admission and death, HR estimates were 0·41 (0·39-0·43) and 0·31 (0·26-0·37), respectively. Omicron versus delta HR estimates varied with age for all endpoints examined. The adjusted HR for hospital admission was 1·10 (0·85-1·42) in those younger than 10 years, decreasing to 0·25 (0·21-0·30) in 60-69-year-olds, and then increasing to 0·47 (0·40-0·56) in those aged at least 80 years. For both variants, past infection gave some protection against death both in vaccinated (HR 0·47 [0·32-0·68]) and unvaccinated (0·18 [0·06-0·57]) cases. In vaccinated cases, past infection offered no additional protection against hospital admission beyond that provided by vaccination (HR 0·96 [0·88-1·04]); however, for unvaccinated cases, past infection gave moderate protection (HR 0·55 [0·48-0·63]). Omicron versus delta HR estimates were lower for hospital admission (0·30 [0·28-0·32]) in unvaccinated cases than the corresponding HR estimated for all cases in the primary analysis. Booster vaccination with an mRNA vaccine was highly protective against hospitalisation and death in omicron cases (HR for hospital admission 8-11 weeks post-booster vs unvaccinated: 0·22 [0·20-0·24]), with the protection afforded after a booster not being affected by the vaccine used for doses 1 and 2.FINDINGSThe adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0·56 (95% CI 0·54-0·58); for hospital admission and death, HR estimates were 0·41 (0·39-0·43) and 0·31 (0·26-0·37), respectively. Omicron versus delta HR estimates varied with age for all endpoints examined. The adjusted HR for hospital admission was 1·10 (0·85-1·42) in those younger than 10 years, decreasing to 0·25 (0·21-0·30) in 60-69-year-olds, and then increasing to 0·47 (0·40-0·56) in those aged at least 80 years. For both variants, past infection gave some protection against death both in vaccinated (HR 0·47 [0·32-0·68]) and unvaccinated (0·18 [0·06-0·57]) cases. In vaccinated cases, past infection offered no additional protection against hospital admission beyond that provided by vaccination (HR 0·96 [0·88-1·04]); however, for unvaccinated cases, past infection gave moderate protection (HR 0·55 [0·48-0·63]). Omicron versus delta HR estimates were lower for hospital admission (0·30 [0·28-0·32]) in unvaccinated cases than the corresponding HR estimated for all cases in the primary analysis. Booster vaccination with an mRNA vaccine was highly protective against hospitalisation and death in omicron cases (HR for hospital admission 8-11 weeks post-booster vs unvaccinated: 0·22 [0·20-0·24]), with the protection afforded after a booster not being affected by the vaccine used for doses 1 and 2.The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks is a larger reduction in intrinsic severity (in unvaccinated individuals) counterbalanced by a reduction in vaccine effectiveness. Documented previous SARS-CoV-2 infection offered some protection against hospitalisation and high protection against death in unvaccinated individuals, but only offered additional protection in vaccinated individuals for the death endpoint. Booster vaccination with mRNA vaccines maintains over 70% protection against hospitalisation and death in breakthrough confirmed omicron infections.INTERPRETATIONThe risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks is a larger reduction in intrinsic severity (in unvaccinated individuals) counterbalanced by a reduction in vaccine effectiveness. Documented previous SARS-CoV-2 infection offered some protection against hospitalisation and high protection against death in unvaccinated individuals, but only offered additional protection in vaccinated individuals for the death endpoint. Booster vaccination with mRNA vaccines maintains over 70% protection against hospitalisation and death in breakthrough confirmed omicron infections.Medical Research Council, UK Research and Innovation, Department of Health and Social Care, National Institute for Health Research, Community Jameel, and Engineering and Physical Sciences Research Council.FUNDINGMedical Research Council, UK Research and Innovation, Department of Health and Social Care, National Institute for Health Research, Community Jameel, and Engineering and Physical Sciences Research Council. |
| Author | Volz, Erik Andrews, Nick Funk, Sebastian Ghani, Azra C Chand, Meera Lopez Bernal, Jamie Flaxman, Seth Presanis, Anne M Hinsley, Wes Seaman, Shaun R Blomquist, Paula Thelwall, Simon Zaidi, Asad Bhatt, Samir Nyberg, Tommy Charlett, Andre Ferguson, Neil M De Angelis, Daniela Aziz, Nurin Abdul Nash, Sophie G Bernal, Jamie Lopez Abdul Aziz, Nurin Webster, Harriet H Hope, Russell Harman, Katie Dabrera, Gavin Abbott, Sam Kall, Meaghan |
| Author_xml | – sequence: 1 givenname: Tommy orcidid: 0000-0002-9436-0626 surname: Nyberg fullname: Nyberg, Tommy email: tommy.nyberg@mrc-bsu.cam.ac.uk organization: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK – sequence: 2 givenname: Neil M orcidid: 0000-0002-1154-8093 surname: Ferguson fullname: Ferguson, Neil M email: neil.ferguson@imperial.ac.uk organization: NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK – sequence: 3 givenname: Sophie G orcidid: 0000-0002-7717-6982 surname: Nash fullname: Nash, Sophie G organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 4 givenname: Harriet H orcidid: 0000-0002-2145-8884 surname: Webster fullname: Webster, Harriet H organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 5 givenname: Seth orcidid: 0000-0002-2477-4217 surname: Flaxman fullname: Flaxman, Seth organization: Department of Computer Science, University of Oxford, Oxford, UK – sequence: 6 givenname: Nick orcidid: 0000-0003-2069-2684 surname: Andrews fullname: Andrews, Nick organization: COVID-19 Surveillance Cell, UK Health Security Agency, London, UK – sequence: 7 givenname: Wes orcidid: 0000-0002-4597-1746 surname: Hinsley fullname: Hinsley, Wes organization: NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK – sequence: 8 givenname: Jamie Lopez orcidid: 0000-0002-1301-5653 surname: Bernal fullname: Bernal, Jamie Lopez organization: NIHR Health Protection Research Unit for Respiratory Infections, Imperial College London, London, UK – sequence: 9 givenname: Meaghan orcidid: 0000-0001-6971-427X surname: Kall fullname: Kall, Meaghan organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 10 givenname: Samir orcidid: 0000-0002-0891-4611 surname: Bhatt fullname: Bhatt, Samir organization: NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK – sequence: 11 givenname: Paula orcidid: 0000-0002-3962-4211 surname: Blomquist fullname: Blomquist, Paula organization: Outbreak Surveillance Team, UK Health Security Agency, London, UK – sequence: 12 givenname: Asad orcidid: 0000-0002-6420-2539 surname: Zaidi fullname: Zaidi, Asad organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 13 givenname: Erik orcidid: 0000-0001-6268-8937 surname: Volz fullname: Volz, Erik organization: NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK – sequence: 14 givenname: Nurin Abdul orcidid: 0000-0002-8098-6935 surname: Aziz fullname: Aziz, Nurin Abdul organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 15 givenname: Katie orcidid: 0000-0003-1387-0200 surname: Harman fullname: Harman, Katie organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 16 givenname: Sebastian orcidid: 0000-0002-2842-3406 surname: Funk fullname: Funk, Sebastian organization: Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK – sequence: 17 givenname: Sam orcidid: 0000-0001-8057-8037 surname: Abbott fullname: Abbott, Sam organization: Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK – sequence: 18 givenname: Tommy surname: Nyberg fullname: Nyberg, Tommy – sequence: 19 givenname: Neil M surname: Ferguson fullname: Ferguson, Neil M – sequence: 20 givenname: Sophie G surname: Nash fullname: Nash, Sophie G – sequence: 21 givenname: Harriet H surname: Webster fullname: Webster, Harriet H – sequence: 22 givenname: Seth surname: Flaxman fullname: Flaxman, Seth – sequence: 23 givenname: Nick surname: Andrews fullname: Andrews, Nick – sequence: 24 givenname: Wes surname: Hinsley fullname: Hinsley, Wes – sequence: 25 givenname: Jamie surname: Lopez Bernal fullname: Lopez Bernal, Jamie – sequence: 26 givenname: Meaghan surname: Kall fullname: Kall, Meaghan – sequence: 27 givenname: Samir surname: Bhatt fullname: Bhatt, Samir – sequence: 28 givenname: Paula surname: Blomquist fullname: Blomquist, Paula – sequence: 29 givenname: Asad surname: Zaidi fullname: Zaidi, Asad – sequence: 30 givenname: Erik surname: Volz fullname: Volz, Erik – sequence: 31 givenname: Nurin surname: Abdul Aziz fullname: Abdul Aziz, Nurin – sequence: 32 givenname: Katie surname: Harman fullname: Harman, Katie – sequence: 33 givenname: Sebastian surname: Funk fullname: Funk, Sebastian – sequence: 34 givenname: Sam surname: Abbott fullname: Abbott, Sam – sequence: 35 givenname: Russell surname: Hope fullname: Hope, Russell – sequence: 36 givenname: Andre surname: Charlett fullname: Charlett, Andre – sequence: 37 givenname: Meera surname: Chand fullname: Chand, Meera – sequence: 38 givenname: Azra C surname: Ghani fullname: Ghani, Azra C – sequence: 39 givenname: Shaun R surname: Seaman fullname: Seaman, Shaun R – sequence: 40 givenname: Gavin surname: Dabrera fullname: Dabrera, Gavin – sequence: 41 givenname: Daniela surname: De Angelis fullname: De Angelis, Daniela – sequence: 42 givenname: Anne M surname: Presanis fullname: Presanis, Anne M – sequence: 43 givenname: Simon surname: Thelwall fullname: Thelwall, Simon – sequence: 44 givenname: Russell orcidid: 0000-0003-2838-6833 surname: Hope fullname: Hope, Russell organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 45 givenname: Andre orcidid: 0000-0001-7154-0432 surname: Charlett fullname: Charlett, Andre organization: NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK – sequence: 46 givenname: Meera orcidid: 0000-0001-9697-0340 surname: Chand fullname: Chand, Meera organization: COVID-19 Genomics Cell, UK Health Security Agency, London, UK – sequence: 47 givenname: Azra C orcidid: 0000-0002-0007-4910 surname: Ghani fullname: Ghani, Azra C organization: NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK – sequence: 48 givenname: Shaun R orcidid: 0000-0003-3726-5937 surname: Seaman fullname: Seaman, Shaun R organization: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK – sequence: 49 givenname: Gavin orcidid: 0000-0003-4606-5945 surname: Dabrera fullname: Dabrera, Gavin organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK – sequence: 50 givenname: Daniela orcidid: 0000-0001-6619-6112 surname: De Angelis fullname: De Angelis, Daniela organization: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK – sequence: 51 givenname: Anne M orcidid: 0000-0003-3078-4427 surname: Presanis fullname: Presanis, Anne M organization: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK – sequence: 52 givenname: Simon orcidid: 0000-0002-0434-2724 surname: Thelwall fullname: Thelwall, Simon organization: COVID-19 National Epidemiology Cell, UK Health Security Agency, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35305296$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkluPEyEYhidmjdtd_QkaEm_ai6nAwFDcqFmb9ZBsYmLVeEco882W3SlUoDX9Rf5N6cFGe7OGEAI878vh_c6KE-cdFMVTgocEk_rFBBOGy1pUdZ_SAcaspqV4UPQIE6zkTHw_KXoH5LQ4i_EWbyjMHxWnFa8wp7LuFb_Gfr7QQSe7AqSd7tbRRuRblGaAgo1328nMx4VNurMxg95lsEEN6DRDOkZvrE7QoJ82zyeXnyfl2H8rKfJza0KG-2-HJLd83mAv7JLerdZEDOkArXSw2qWIrENX7qbL1EukkfEzHxKKadmsHxcPW91FeLIfz4uv766-jD-U15_efxxfXpeGM5nKumKcaQ4jrhmdEiEEZaatm4ZQKg2IVrYSpGxIW5EaT7FupwDUVFCx3E1dnRevd76L5XQOjQGXgu7UIti5DmvltVX_7jg7Uzd-pUaS1oxU2aC_Nwj-xxJiUnMbDXT5UeCXUWUKS8ml2KDPj9Bbvww5gy3FR4RVeJSpZ3_f6HCVPxlmgO-A_NsxBmgPCMFqUytqWytqUwiKUrWtFSWy7uJIZ3LGm3zzw2x3r_rNTg05jZWFoKKx4Aw0NoBJqvH2XodXRw6ms84a3d3B-j_0vwGvoOnF |
| CitedBy_id | crossref_primary_10_1056_NEJMoa2311330 crossref_primary_10_1371_journal_pone_0305522 crossref_primary_10_3390_v15030802 crossref_primary_10_3390_biomedicines10051002 crossref_primary_10_1002_adfm_202306145 crossref_primary_10_3390_vaccines10111944 crossref_primary_10_1038_s41598_024_76401_1 crossref_primary_10_1186_s12985_022_01940_w crossref_primary_10_1111_imj_16368 crossref_primary_10_1002_14651858_CD013600_pub6 crossref_primary_10_1016_j_gene_2024_148970 crossref_primary_10_1164_rccm_202410_2036PP crossref_primary_10_1002_jmv_28186 crossref_primary_10_7759_cureus_91816 crossref_primary_10_3390_v15030811 crossref_primary_10_1016_S0140_6736_22_01586_0 crossref_primary_10_1186_s12985_024_02538_0 crossref_primary_10_3390_vaccines11020451 crossref_primary_10_1093_pnasnexus_pgae500 crossref_primary_10_1016_j_jtbi_2022_111336 crossref_primary_10_3389_fpubh_2022_961030 crossref_primary_10_1016_j_jaci_2024_10_013 crossref_primary_10_1038_s41467_023_37673_9 crossref_primary_10_1038_s41375_024_02336_1 crossref_primary_10_1080_14656566_2022_2131395 crossref_primary_10_3390_v15010180 crossref_primary_10_1186_s12879_024_09889_7 crossref_primary_10_1016_j_vaccine_2022_10_053 crossref_primary_10_1177_08968608231221952 crossref_primary_10_1371_journal_pone_0271446 crossref_primary_10_3390_v14051074 crossref_primary_10_1007_s10157_025_02740_6 crossref_primary_10_3389_fpubh_2023_1143650 crossref_primary_10_3390_vaccines12010058 crossref_primary_10_7554_eLife_78933 crossref_primary_10_3390_vaccines12010059 crossref_primary_10_1016_j_jiph_2023_08_010 crossref_primary_10_1002_hsr2_2207 crossref_primary_10_1016_j_compbiomed_2022_105969 crossref_primary_10_1017_ash_2023_489 crossref_primary_10_1186_s12889_024_19510_w crossref_primary_10_1128_spectrum_00932_24 crossref_primary_10_1136_bmj_2022_071932 crossref_primary_10_3390_ijerph20042779 crossref_primary_10_3390_jcm12062279 crossref_primary_10_1016_S0140_6736_22_00929_1 crossref_primary_10_7554_eLife_75427 crossref_primary_10_1007_s00277_023_05572_0 crossref_primary_10_1016_j_ymthe_2023_09_002 crossref_primary_10_1056_NEJMc2203679 crossref_primary_10_3389_fmed_2022_912367 crossref_primary_10_1017_S1446181123000123 crossref_primary_10_1097_TP_0000000000004873 crossref_primary_10_1111_ene_15843 crossref_primary_10_1016_j_cmi_2022_12_020 crossref_primary_10_1111_add_16196 crossref_primary_10_1016_j_tranon_2022_101605 crossref_primary_10_1016_j_jhlto_2025_100362 crossref_primary_10_1186_s41479_022_00099_w crossref_primary_10_3143_geriatrics_62_250 crossref_primary_10_1016_S1473_3099_24_00258_5 crossref_primary_10_1186_s12889_023_15701_z crossref_primary_10_3389_fpubh_2025_1447738 crossref_primary_10_1016_j_transproceed_2024_12_013 crossref_primary_10_4009_jsdt_58_347 crossref_primary_10_1016_j_lanwpc_2022_100675 crossref_primary_10_1136_bmj_o1806 crossref_primary_10_7189_jogh_14_05009 crossref_primary_10_1097_CCM_0000000000005950 crossref_primary_10_3390_diagnostics13030559 crossref_primary_10_1016_j_virs_2022_11_007 crossref_primary_10_1182_bloodadvances_2022008827 crossref_primary_10_1017_S0950268823001358 crossref_primary_10_3390_life13010183 crossref_primary_10_3390_vaccines11050920 crossref_primary_10_1093_jac_dkae163 crossref_primary_10_1080_22221751_2022_2093135 crossref_primary_10_1038_s41467_023_38275_1 crossref_primary_10_1002_cam4_6678 crossref_primary_10_1136_bmjebm_2022_112064 crossref_primary_10_1177_2632010X221124908 crossref_primary_10_1093_infdis_jiac449 crossref_primary_10_22207_JPAM_16_4_42 crossref_primary_10_1186_s12879_022_07781_w crossref_primary_10_1097_BOR_0000000000000930 crossref_primary_10_3389_fpubh_2023_1157824 crossref_primary_10_1038_s41598_024_73664_6 crossref_primary_10_1016_j_resinv_2023_08_010 crossref_primary_10_23749_mdl_v113i2_13108 crossref_primary_10_1038_s41579_025_01185_8 crossref_primary_10_3389_fped_2023_1214768 crossref_primary_10_1007_s13206_022_00078_9 crossref_primary_10_3389_fnagi_2023_1138418 crossref_primary_10_1186_s12859_024_05648_2 crossref_primary_10_1038_s41467_023_37697_1 crossref_primary_10_1016_j_ijid_2022_08_026 crossref_primary_10_3389_fcimb_2023_1249069 crossref_primary_10_3389_fcimb_2023_1207225 crossref_primary_10_1111_ped_15777 crossref_primary_10_1038_s41467_022_32121_6 crossref_primary_10_3390_jcm12103500 crossref_primary_10_1016_S2213_2600_22_00360_5 crossref_primary_10_3390_vaccines10111914 crossref_primary_10_1126_sciimmunol_adp8170 crossref_primary_10_2147_IDR_S412657 crossref_primary_10_1128_jvi_00139_24 crossref_primary_10_1016_j_cmi_2022_05_027 crossref_primary_10_1080_07853890_2024_2307504 crossref_primary_10_1001_jamanetworkopen_2023_7243 crossref_primary_10_1038_s41579_023_01001_1 crossref_primary_10_1371_journal_pone_0301330 crossref_primary_10_1016_j_vaccine_2025_127290 crossref_primary_10_2147_JIR_S375494 crossref_primary_10_3389_fpubh_2022_986743 crossref_primary_10_1016_j_imj_2025_100169 crossref_primary_10_1097_INF_0000000000004213 crossref_primary_10_1093_cid_ciad143 crossref_primary_10_1093_infdis_jiad324 crossref_primary_10_1016_j_resinv_2024_11_008 crossref_primary_10_2196_45513 crossref_primary_10_1093_jac_dkad275 crossref_primary_10_3389_fimmu_2023_1130539 crossref_primary_10_3390_vaccines11121791 crossref_primary_10_1007_s12326_022_00516_3 crossref_primary_10_1016_j_ijmmb_2022_12_004 crossref_primary_10_3389_fpubh_2022_1028062 crossref_primary_10_1016_j_cmet_2023_02_016 crossref_primary_10_1016_j_ijregi_2023_02_002 crossref_primary_10_1126_science_abq4411 crossref_primary_10_1016_j_jinf_2022_10_040 crossref_primary_10_1371_journal_pone_0303176 crossref_primary_10_1093_aje_kwae280 crossref_primary_10_1080_10428194_2023_2243355 crossref_primary_10_1001_jamanetworkopen_2023_9694 crossref_primary_10_1001_jamanetworkopen_2022_27357 crossref_primary_10_1038_s41598_025_98788_1 crossref_primary_10_1016_j_ijid_2024_107016 crossref_primary_10_3389_fmed_2022_1027708 crossref_primary_10_1016_S2213_2600_22_00438_6 crossref_primary_10_1016_j_ijid_2024_107021 crossref_primary_10_1371_journal_pmed_1004086 crossref_primary_10_3390_vaccines10101762 crossref_primary_10_1002_ajh_26626 crossref_primary_10_1016_j_ebiom_2023_104916 crossref_primary_10_1155_2024_2041317 crossref_primary_10_3389_fmed_2022_1010489 crossref_primary_10_1016_j_ijid_2023_04_410 crossref_primary_10_1371_journal_pgph_0001445 crossref_primary_10_1016_j_chaos_2025_116782 crossref_primary_10_1016_j_ejim_2023_11_031 crossref_primary_10_1016_j_lana_2022_100297 crossref_primary_10_1016_j_jinf_2022_10_029 crossref_primary_10_1038_s41598_022_24918_8 crossref_primary_10_1016_j_pcad_2022_11_014 crossref_primary_10_1007_s12033_024_01146_1 crossref_primary_10_1016_j_eimce_2022_11_021 crossref_primary_10_1007_s12530_023_09558_1 crossref_primary_10_1016_j_heliyon_2024_e39044 crossref_primary_10_3390_v15112153 crossref_primary_10_1002_cam4_6657 crossref_primary_10_1371_journal_pbio_3002118 crossref_primary_10_1016_j_biopha_2022_113522 crossref_primary_10_1016_j_pediatrneurol_2025_08_018 crossref_primary_10_1002_jmv_28138 crossref_primary_10_1002_jmv_28131 crossref_primary_10_7554_eLife_79639 crossref_primary_10_1016_j_puhe_2022_10_014 crossref_primary_10_1007_s12325_025_03112_y crossref_primary_10_3390_vaccines13060588 crossref_primary_10_1186_s12879_023_08538_9 crossref_primary_10_1128_jvi_01351_23 crossref_primary_10_3389_fpubh_2025_1488283 crossref_primary_10_1038_s41576_023_00610_z crossref_primary_10_7759_cureus_38586 crossref_primary_10_1007_s40620_023_01640_w crossref_primary_10_15829_1728_8800_2022_3228 crossref_primary_10_1080_22423982_2022_2109562 crossref_primary_10_1186_s12879_022_07819_z crossref_primary_10_1016_j_jiac_2024_06_015 crossref_primary_10_1002_cam4_70134 crossref_primary_10_3389_fmicb_2022_889643 crossref_primary_10_4103_DSHMJ_DSHMJ_1_25 crossref_primary_10_1186_s12913_024_11493_z crossref_primary_10_3390_life12081184 crossref_primary_10_2147_RMHP_S463062 crossref_primary_10_3201_eid2807_220033 crossref_primary_10_3390_v15010149 crossref_primary_10_1007_s11684_022_0961_y crossref_primary_10_3390_vaccines10071131 crossref_primary_10_1007_s11538_024_01275_3 crossref_primary_10_1007_s00408_022_00566_7 crossref_primary_10_1016_j_clinthera_2025_07_006 crossref_primary_10_1136_gutjnl_2022_327409 crossref_primary_10_1007_s40121_022_00683_z crossref_primary_10_1016_S0140_6736_22_01185_0 crossref_primary_10_1136_bmjgh_2022_010690 crossref_primary_10_1097_CCE_0000000000001021 crossref_primary_10_3390_jcm11216600 crossref_primary_10_1001_jamanetworkopen_2023_19766 crossref_primary_10_3390_microorganisms12030440 crossref_primary_10_3390_v17020274 crossref_primary_10_1093_eurpub_ckad094 crossref_primary_10_1007_s10238_022_00964_4 crossref_primary_10_3390_jcm12247575 crossref_primary_10_1093_ofid_ofac636 crossref_primary_10_1093_ofid_ofac638 crossref_primary_10_1016_j_lana_2024_100693 crossref_primary_10_3390_vaccines12050515 crossref_primary_10_3389_fimmu_2022_958418 crossref_primary_10_1186_s12879_023_08658_2 crossref_primary_10_1099_mgen_0_001018 crossref_primary_10_1186_s12879_023_08527_y crossref_primary_10_1155_2022_4677720 crossref_primary_10_3390_vaccines13060554 crossref_primary_10_1001_jamanetworkopen_2023_54991 crossref_primary_10_1080_24709360_2024_2340163 crossref_primary_10_1016_j_medj_2023_02_004 crossref_primary_10_1097_INF_0000000000003791 crossref_primary_10_1093_jpids_piac074 crossref_primary_10_1002_jmv_29268 crossref_primary_10_1093_cid_ciad424 crossref_primary_10_1038_s41598_024_53656_2 crossref_primary_10_1038_s41467_023_39661_5 crossref_primary_10_1016_S1473_3099_22_00345_0 crossref_primary_10_1186_s41479_025_00158_y crossref_primary_10_3390_vaccines11071133 crossref_primary_10_1093_cid_ciac571 crossref_primary_10_1093_cid_ciad660 crossref_primary_10_1109_JTEHM_2022_3208057 crossref_primary_10_3201_eid2809_220613 crossref_primary_10_1016_j_medj_2023_08_006 crossref_primary_10_1093_cid_ciac324 crossref_primary_10_1002_rmv_2373 crossref_primary_10_1038_s41583_023_00769_8 crossref_primary_10_1016_j_jinf_2024_106292 crossref_primary_10_1016_j_jiph_2024_102502 crossref_primary_10_1016_j_jinf_2023_05_019 crossref_primary_10_1093_jac_dkad309 crossref_primary_10_1038_s41598_023_32639_9 crossref_primary_10_3390_v15041017 crossref_primary_10_1038_s41467_022_33378_7 crossref_primary_10_1002_jmv_28875 crossref_primary_10_3390_vaccines10101699 crossref_primary_10_1016_j_ccell_2022_04_015 crossref_primary_10_1007_s00405_025_09458_x crossref_primary_10_1097_ID9_0000000000000081 crossref_primary_10_1016_j_ebiom_2023_104753 crossref_primary_10_1186_s41100_024_00520_8 crossref_primary_10_1002_ijc_34798 crossref_primary_10_2147_IDR_S492816 crossref_primary_10_1128_spectrum_01736_22 crossref_primary_10_1016_j_ijregi_2024_100408 crossref_primary_10_3389_fpubh_2022_1006631 crossref_primary_10_1016_j_jiac_2023_11_010 crossref_primary_10_1016_j_ajt_2023_09_022 crossref_primary_10_1136_bmj_2022_074521 crossref_primary_10_1001_jamanetworkopen_2022_53590 crossref_primary_10_3390_vaccines10070986 crossref_primary_10_1371_journal_pone_0298218 crossref_primary_10_3389_ti_2022_10721 crossref_primary_10_1371_journal_pone_0299304 crossref_primary_10_1016_S0140_6736_22_02467_9 crossref_primary_10_1016_S1473_3099_22_00729_0 crossref_primary_10_3201_eid2810_221058 crossref_primary_10_1007_s00277_023_05413_0 crossref_primary_10_1371_journal_pcbi_1012964 crossref_primary_10_1093_jac_dkac433 crossref_primary_10_3390_vaccines12111245 crossref_primary_10_1016_S2213_2600_23_00015_2 crossref_primary_10_3389_fpubh_2022_1038296 crossref_primary_10_1080_14760584_2022_2130773 crossref_primary_10_1038_s41392_024_02066_x crossref_primary_10_1093_rheumatology_kead449 crossref_primary_10_1002_jmv_28418 crossref_primary_10_1128_spectrum_02980_23 crossref_primary_10_1002_ctm2_880 crossref_primary_10_1016_j_jiac_2025_102721 crossref_primary_10_3389_fimmu_2022_1044025 crossref_primary_10_1126_sciimmunol_adn0178 crossref_primary_10_1183_13993003_02440_2022 crossref_primary_10_1146_annurev_ecolsys_102320_101234 crossref_primary_10_1038_s41564_022_01123_x crossref_primary_10_1001_jamanetworkopen_2022_55599 crossref_primary_10_1007_s11606_022_08007_0 crossref_primary_10_3389_fped_2023_1156366 crossref_primary_10_3389_fneur_2025_1577976 crossref_primary_10_1111_bjh_18690 crossref_primary_10_1245_s10434_024_16297_3 crossref_primary_10_3389_fneur_2024_1367974 crossref_primary_10_1016_j_jtbi_2024_111771 crossref_primary_10_1001_jamapediatrics_2023_2357 crossref_primary_10_3390_v14122622 crossref_primary_10_3390_covid5090156 crossref_primary_10_1161_CIRCRESAHA_123_321878 crossref_primary_10_1186_s12911_023_02310_4 crossref_primary_10_1093_ofid_ofad330 crossref_primary_10_1016_j_ejor_2023_08_011 crossref_primary_10_1111_pai_13928 crossref_primary_10_1186_s12879_024_09520_9 crossref_primary_10_1136_bmj_2022_073639 crossref_primary_10_1073_pnas_2311573120 crossref_primary_10_1097_ID9_0000000000000078 crossref_primary_10_1016_S1473_3099_22_00595_3 crossref_primary_10_1016_j_jinf_2022_11_026 crossref_primary_10_1016_j_lansea_2022_100121 crossref_primary_10_1080_0886022X_2025_2512053 crossref_primary_10_3390_healthcare10091684 crossref_primary_10_3389_fpubh_2022_984433 crossref_primary_10_2147_IDR_S479896 crossref_primary_10_1016_j_cyto_2024_156592 crossref_primary_10_1371_journal_pone_0290937 crossref_primary_10_3390_antibiotics12020393 crossref_primary_10_1002_jmv_29300 crossref_primary_10_3390_vaccines10122117 crossref_primary_10_1093_infdis_jiad194 crossref_primary_10_3390_jcm11216348 crossref_primary_10_3390_vaccines11030668 crossref_primary_10_1002_jpen_2410 crossref_primary_10_1186_s12889_024_18576_w crossref_primary_10_1017_ash_2024_352 crossref_primary_10_1002_ppul_26644 crossref_primary_10_12688_f1000research_143776_2 crossref_primary_10_12688_f1000research_143776_1 crossref_primary_10_7759_cureus_52055 crossref_primary_10_1371_journal_pone_0294025 crossref_primary_10_1177_00469580241246466 crossref_primary_10_1148_radiol_222730 crossref_primary_10_1016_j_watres_2022_118809 crossref_primary_10_3390_v14061297 crossref_primary_10_1038_s41467_023_40568_4 crossref_primary_10_1016_j_ijid_2023_10_013 crossref_primary_10_1016_S2665_9913_22_00221_1 crossref_primary_10_1093_abt_tbae009 crossref_primary_10_3390_ijms25021353 crossref_primary_10_1007_s43538_023_00176_8 crossref_primary_10_1038_s41467_023_38127_y crossref_primary_10_1136_bmjgh_2023_012328 crossref_primary_10_1186_s12879_024_09633_1 crossref_primary_10_3389_fpubh_2023_1195908 crossref_primary_10_1007_s12015_022_10477_y crossref_primary_10_1016_S1473_3099_22_00801_5 crossref_primary_10_3390_v17040500 crossref_primary_10_1093_cid_ciac957 crossref_primary_10_1016_j_ebiom_2022_104035 crossref_primary_10_1016_j_jcv_2022_105299 crossref_primary_10_1038_s41467_022_32404_y crossref_primary_10_1111_all_15593 crossref_primary_10_1016_j_apsb_2023_08_023 crossref_primary_10_1016_j_healun_2023_10_010 crossref_primary_10_1093_oxfimm_iqac003 crossref_primary_10_3389_fimmu_2024_1330178 crossref_primary_10_1093_cid_ciac705 crossref_primary_10_1186_s12879_022_07878_2 crossref_primary_10_1016_j_clinthera_2023_07_018 crossref_primary_10_3390_v15020508 crossref_primary_10_1590_1413_81232025307_19502024en crossref_primary_10_1016_j_epidem_2022_100657 crossref_primary_10_3389_fpubh_2024_1294261 crossref_primary_10_1017_ice_2023_95 crossref_primary_10_1016_j_jinf_2024_106233 crossref_primary_10_1186_s42466_023_00243_x crossref_primary_10_1111_apt_18349 crossref_primary_10_1093_cid_ciac933 crossref_primary_10_3389_fmed_2023_1229794 crossref_primary_10_1016_j_jfma_2023_08_029 crossref_primary_10_1093_jnen_nlad015 crossref_primary_10_3390_antibiotics13090842 crossref_primary_10_1016_j_biopha_2022_113499 crossref_primary_10_3389_fimmu_2022_1061686 crossref_primary_10_1001_jamanetworkopen_2022_48664 crossref_primary_10_1017_S0950268823000420 crossref_primary_10_1186_s12913_025_12878_4 crossref_primary_10_1002_jmv_27974 crossref_primary_10_1002_iid3_733 crossref_primary_10_3390_v14061255 crossref_primary_10_1002_mco2_426 crossref_primary_10_1155_cjid_4601882 crossref_primary_10_3390_biomedicines13071563 crossref_primary_10_1371_journal_pone_0300306 crossref_primary_10_1093_cid_ciac921 crossref_primary_10_1038_s41541_024_00933_w crossref_primary_10_3390_cancers15112993 crossref_primary_10_1016_j_ccrj_2024_11_003 crossref_primary_10_1038_s41467_024_52668_w crossref_primary_10_3389_fimmu_2022_984376 crossref_primary_10_3390_vaccines12080926 crossref_primary_10_1002_jmv_28831 crossref_primary_10_1001_jamanetworkopen_2022_47341 crossref_primary_10_3390_microorganisms11010030 crossref_primary_10_1016_j_immuni_2022_05_018 crossref_primary_10_1038_s41591_023_02414_4 crossref_primary_10_1016_j_imbio_2023_152720 crossref_primary_10_1097_MD_0000000000031740 crossref_primary_10_3390_microorganisms11040925 crossref_primary_10_3390_v15101994 crossref_primary_10_1186_s12967_022_03770_4 crossref_primary_10_1111_ajt_17141 crossref_primary_10_1002_mco2_642 crossref_primary_10_1016_j_vaccine_2022_10_014 crossref_primary_10_1016_j_semarthrit_2022_152129 crossref_primary_10_1111_bjh_18823 crossref_primary_10_1002_jmv_28847 crossref_primary_10_3389_fpubh_2023_1273443 crossref_primary_10_3390_clinpract14030055 crossref_primary_10_3390_v17071000 crossref_primary_10_1038_s41598_024_64668_3 crossref_primary_10_3389_fmed_2022_822821 crossref_primary_10_1053_j_gastro_2022_09_015 crossref_primary_10_2196_48134 crossref_primary_10_3390_medsci10040058 crossref_primary_10_1159_000536521 crossref_primary_10_1038_s41467_023_37541_6 crossref_primary_10_1371_journal_ppat_1011432 crossref_primary_10_3390_microorganisms10091688 crossref_primary_10_1016_j_ijid_2023_04_399 crossref_primary_10_1016_j_acra_2025_01_006 crossref_primary_10_1016_j_jinf_2022_07_029 crossref_primary_10_1128_spectrum_02368_23 crossref_primary_10_3390_microorganisms12122573 crossref_primary_10_3390_jcm12185904 crossref_primary_10_1371_journal_pone_0292017 crossref_primary_10_1080_21645515_2023_2214495 crossref_primary_10_3390_v16030328 crossref_primary_10_1111_all_15502 crossref_primary_10_1017_S0950268823000572 crossref_primary_10_1177_25424823251377732 crossref_primary_10_3389_fimmu_2023_1139620 crossref_primary_10_29254_2077_4214_2024_3_174_108_117 crossref_primary_10_1007_s40121_022_00729_2 crossref_primary_10_1080_14760584_2024_2383343 crossref_primary_10_1038_s41598_023_47043_6 crossref_primary_10_1186_s40001_023_01482_z crossref_primary_10_1093_ofid_ofae065 crossref_primary_10_3390_v14081603 crossref_primary_10_1038_s41579_022_00841_7 crossref_primary_10_1136_ard_2022_222954 crossref_primary_10_3390_ijms231911291 crossref_primary_10_3390_healthcare11030289 crossref_primary_10_1007_s00277_024_05744_6 crossref_primary_10_1016_j_mayocpiqo_2025_100642 crossref_primary_10_1016_j_heliyon_2024_e25618 crossref_primary_10_3390_jcm14144894 crossref_primary_10_1016_j_jiph_2023_01_013 crossref_primary_10_1186_s40795_023_00816_8 crossref_primary_10_1038_s41598_023_35068_w crossref_primary_10_1182_blood_2022017257 crossref_primary_10_1016_j_bjid_2025_104509 crossref_primary_10_1016_j_jtct_2022_04_017 crossref_primary_10_1126_scitranslmed_adi0979 crossref_primary_10_1002_jmv_29183 crossref_primary_10_1016_j_transproceed_2022_07_003 crossref_primary_10_1001_jamanetworkopen_2022_46152 crossref_primary_10_3389_fimmu_2022_916686 crossref_primary_10_1016_j_cjtee_2025_02_003 crossref_primary_10_7326_M22_2202 crossref_primary_10_1016_j_jcv_2025_105833 crossref_primary_10_1007_s15010_025_02583_z crossref_primary_10_1128_spectrum_05163_22 crossref_primary_10_1016_j_atherosclerosis_2025_120449 crossref_primary_10_1016_j_cmi_2023_06_016 crossref_primary_10_1136_bmjph_2024_001888 crossref_primary_10_1186_s12920_023_01637_1 crossref_primary_10_1016_j_puhip_2024_100535 crossref_primary_10_9778_cmajo_20220194 crossref_primary_10_3390_v15071430 crossref_primary_10_1016_j_rmed_2025_108306 crossref_primary_10_4103_jgid_jgid_93_24 crossref_primary_10_1016_j_retram_2023_103402 crossref_primary_10_3390_v17050625 crossref_primary_10_1016_j_envres_2023_115612 crossref_primary_10_1016_j_vaccine_2023_11_047 crossref_primary_10_1016_S0140_6736_22_01432_5 crossref_primary_10_1109_ACCESS_2022_3197587 crossref_primary_10_3390_vaccines11111684 crossref_primary_10_1016_j_lanwpc_2023_100829 crossref_primary_10_3390_vaccines12050466 crossref_primary_10_1016_j_lana_2023_100461 crossref_primary_10_1038_s41598_023_48272_5 crossref_primary_10_1080_23744235_2023_2276784 crossref_primary_10_1016_j_jhin_2025_07_002 crossref_primary_10_1093_cid_ciad287 crossref_primary_10_3390_ijms26031263 crossref_primary_10_1016_j_ijmedinf_2023_105039 crossref_primary_10_1186_s12879_023_08181_4 crossref_primary_10_1016_j_heliyon_2024_e37617 crossref_primary_10_1016_j_ijmmb_2023_100391 crossref_primary_10_1093_aje_kwad081 crossref_primary_10_1016_j_vaccine_2023_04_034 crossref_primary_10_1093_ofid_ofaf185 crossref_primary_10_1183_23120541_00277_2024 crossref_primary_10_3390_vaccines13070738 crossref_primary_10_3390_vaccines10071070 crossref_primary_10_3389_fpubh_2023_1150095 crossref_primary_10_1038_s41467_023_39189_8 crossref_primary_10_1111_anae_16061 crossref_primary_10_3389_fmicb_2022_1095068 crossref_primary_10_1371_journal_pone_0290221 crossref_primary_10_1038_s41591_022_01887_z crossref_primary_10_1093_cid_ciad266 crossref_primary_10_1080_00036846_2023_2210816 crossref_primary_10_1016_S0140_6736_22_01469_6 crossref_primary_10_2147_RMHP_S402813 crossref_primary_10_1038_s41467_025_60885_0 crossref_primary_10_1038_s41598_024_54366_5 crossref_primary_10_3390_antibiotics12010088 crossref_primary_10_1186_s12890_025_03613_0 crossref_primary_10_3390_vaccines11081342 crossref_primary_10_1186_s12941_024_00750_y crossref_primary_10_3390_microorganisms11030787 crossref_primary_10_22207_JPAM_17_3_46 crossref_primary_10_1016_j_csbj_2025_05_033 crossref_primary_10_1016_j_ijid_2022_12_018 crossref_primary_10_3390_pathogens12020354 crossref_primary_10_3390_v15020297 crossref_primary_10_1002_jmv_28477 crossref_primary_10_1002_jmv_29326 crossref_primary_10_3390_pathogens13030267 crossref_primary_10_1136_ard_2022_222904 crossref_primary_10_1007_s44370_025_00010_3 crossref_primary_10_1111_joim_13646 crossref_primary_10_1186_s12985_023_02144_6 crossref_primary_10_1111_bph_16262 crossref_primary_10_3389_fmed_2022_1038938 crossref_primary_10_1016_S0140_6736_23_01425_3 crossref_primary_10_1371_journal_pone_0302199 crossref_primary_10_1016_j_cmi_2022_08_002 crossref_primary_10_1111_tid_14332 crossref_primary_10_1093_jac_dkad132 crossref_primary_10_1016_j_ajic_2025_08_021 crossref_primary_10_1080_14760584_2023_2158816 crossref_primary_10_3389_fpubh_2022_1018399 crossref_primary_10_1016_S2213_2600_24_00179_6 crossref_primary_10_1016_j_jiph_2022_12_007 crossref_primary_10_1093_aje_kwad058 crossref_primary_10_1016_j_jiph_2022_12_005 crossref_primary_10_1007_s40121_024_00965_8 crossref_primary_10_1016_j_jiph_2025_102733 crossref_primary_10_1002_jmv_28497 crossref_primary_10_1038_s41598_025_10447_7 crossref_primary_10_1016_j_cmi_2022_08_019 crossref_primary_10_1002_jmv_29342 crossref_primary_10_1038_s41467_022_31402_4 crossref_primary_10_3389_fimmu_2022_1034444 crossref_primary_10_36425_rehab121733 crossref_primary_10_1097_CCE_0000000000001122 crossref_primary_10_3389_fimmu_2023_1146196 crossref_primary_10_3390_microorganisms13030641 crossref_primary_10_3390_v15081636 crossref_primary_10_1007_s15010_023_01996_y crossref_primary_10_1038_s41467_022_33910_9 crossref_primary_10_14785_lymphosign_2024_0007 crossref_primary_10_3390_cimb46110703 crossref_primary_10_1371_journal_pone_0304110 crossref_primary_10_1080_14760584_2023_2143347 crossref_primary_10_1111_anae_15844 crossref_primary_10_1371_journal_pcbi_1012630 crossref_primary_10_1016_j_jinf_2023_04_015 crossref_primary_10_1111_rssa_12957 crossref_primary_10_1016_j_jiac_2024_04_007 crossref_primary_10_1182_blood_2022017071 crossref_primary_10_3390_jcm12186103 crossref_primary_10_3389_ijph_2024_1606792 crossref_primary_10_1093_ofid_ofac527 crossref_primary_10_1007_s00296_023_05314_5 crossref_primary_10_7189_jogh_12_03067 crossref_primary_10_1007_s00508_022_02098_9 crossref_primary_10_1016_j_ijid_2022_11_006 crossref_primary_10_1590_1413_81232025307_19502024 crossref_primary_10_2174_0115734099275132231213055138 crossref_primary_10_3390_jcm11185273 crossref_primary_10_1136_bmj_p1111 crossref_primary_10_1038_s41467_023_37813_1 crossref_primary_10_1038_s41541_022_00580_z crossref_primary_10_1093_ofid_ofad612 crossref_primary_10_3389_fphar_2023_1266915 crossref_primary_10_1093_ofid_ofac517 crossref_primary_10_1007_s13385_024_00400_9 crossref_primary_10_1016_j_healun_2023_01_012 crossref_primary_10_1016_S0140_6736_22_02465_5 crossref_primary_10_1515_cclm_2023_1487 crossref_primary_10_1016_j_idc_2022_11_001 crossref_primary_10_5415_apallergy_0000000000000188 crossref_primary_10_3390_vaccines11040863 crossref_primary_10_1001_jamanetworkopen_2023_21985 crossref_primary_10_1093_infdis_jiad236 crossref_primary_10_1038_s41598_023_45700_4 crossref_primary_10_1093_infdis_jiac385 crossref_primary_10_1016_j_mayocpiqo_2023_07_004 crossref_primary_10_1186_s12889_025_22021_x crossref_primary_10_2147_COPD_S433269 crossref_primary_10_1371_journal_pone_0282806 crossref_primary_10_1038_s41598_023_42727_5 crossref_primary_10_1097_MD_0000000000033024 crossref_primary_10_7326_M24_0199 crossref_primary_10_1186_s12889_024_17790_w crossref_primary_10_1186_s12985_023_02186_w crossref_primary_10_1093_ckj_sfac174 crossref_primary_10_2147_IDR_S399622 crossref_primary_10_3389_fimmu_2025_1597333 crossref_primary_10_7554_eLife_80556 crossref_primary_10_1080_23744235_2023_2244586 crossref_primary_10_1016_j_ijid_2025_107924 crossref_primary_10_1080_22221751_2022_2063073 crossref_primary_10_1093_jpids_piad010 crossref_primary_10_3390_vaccines12080855 crossref_primary_10_1093_infdis_jiad040 crossref_primary_10_1007_s11739_022_03162_y crossref_primary_10_3390_v17040477 crossref_primary_10_1056_NEJMc2206277 crossref_primary_10_1007_s44411_024_00010_7 crossref_primary_10_1016_j_physa_2023_129243 crossref_primary_10_1186_s12882_023_03258_3 crossref_primary_10_3390_audiolres12060065 crossref_primary_10_1016_j_ebiom_2023_104843 crossref_primary_10_1007_s44411_025_00327_x crossref_primary_10_1002_hsr2_1703 crossref_primary_10_1002_jmv_28747 crossref_primary_10_1093_ofid_ofac332 crossref_primary_10_1093_ofid_ofad415 crossref_primary_10_1016_j_bjid_2024_103737 crossref_primary_10_2174_011573398X268050231031112211 crossref_primary_10_58888_2957_3912_20230207_1 crossref_primary_10_1016_j_jgg_2023_10_003 crossref_primary_10_1128_jvi_00961_22 crossref_primary_10_2337_dc24_1003 crossref_primary_10_1097_CCM_0000000000006271 crossref_primary_10_3389_fpubh_2023_1174944 crossref_primary_10_1016_j_jiph_2022_11_030 crossref_primary_10_1016_j_jinf_2025_106485 crossref_primary_10_3390_vaccines12080883 crossref_primary_10_1016_j_jcvp_2023_100175 crossref_primary_10_1007_s42977_023_00159_2 crossref_primary_10_1186_s12879_023_08407_5 crossref_primary_10_1016_S1473_3099_23_00011_7 crossref_primary_10_1007_s00059_023_05183_5 crossref_primary_10_1038_s43856_025_01086_0 crossref_primary_10_3390_tropicalmed8060330 crossref_primary_10_1093_infdis_jiad260 crossref_primary_10_1016_j_jiph_2022_10_028 crossref_primary_10_1136_bmj_2022_071374 crossref_primary_10_1186_s12879_023_08869_7 crossref_primary_10_3390_diseases10040100 crossref_primary_10_1016_S2213_2600_23_00408_3 crossref_primary_10_3389_fimmu_2022_1010140 crossref_primary_10_1016_j_idnow_2023_104833 crossref_primary_10_3390_vaccines12040379 crossref_primary_10_1001_jamanetworkopen_2023_41936 crossref_primary_10_1186_s12879_023_08714_x crossref_primary_10_1016_j_ijid_2022_06_005 crossref_primary_10_3389_fmicb_2024_1466980 crossref_primary_10_1148_radiol_222462 crossref_primary_10_1093_ije_dyad116 crossref_primary_10_3390_v14071359 crossref_primary_10_1016_j_jiac_2025_102802 crossref_primary_10_1093_infdis_jiae364 crossref_primary_10_1016_j_vaccine_2024_01_101 crossref_primary_10_3389_fpubh_2023_1157363 crossref_primary_10_1097_CCM_0000000000006295 crossref_primary_10_1186_s12879_025_10585_3 crossref_primary_10_1001_jamanetworkopen_2022_45861 crossref_primary_10_1186_s12873_025_01279_9 crossref_primary_10_3390_v14122736 crossref_primary_10_1080_22221751_2023_2220578 crossref_primary_10_1007_s00018_025_05822_6 crossref_primary_10_1016_j_jamda_2023_01_006 crossref_primary_10_1002_jmv_28786 crossref_primary_10_1016_S2215_0366_22_00260_7 crossref_primary_10_1038_s41577_022_00716_1 crossref_primary_10_1186_s12879_022_07777_6 crossref_primary_10_1002_mco2_143 crossref_primary_10_3389_fpubh_2024_1327093 crossref_primary_10_1007_s11684_024_1074_6 crossref_primary_10_1038_s43856_023_00261_5 crossref_primary_10_1371_journal_pone_0284130 crossref_primary_10_1016_j_ijid_2023_01_027 crossref_primary_10_3390_cancers17060999 crossref_primary_10_3390_healthcare11152184 crossref_primary_10_1016_S1473_3099_24_00217_2 crossref_primary_10_3390_v15051132 crossref_primary_10_1136_bmj_2022_070695 crossref_primary_10_1016_S2468_2667_23_00079_8 crossref_primary_10_1016_j_cmi_2024_10_026 crossref_primary_10_1097_MCP_0000000000000953 crossref_primary_10_1016_j_jhin_2022_12_014 crossref_primary_10_1038_s41598_024_64044_1 crossref_primary_10_1093_ofid_ofad216 crossref_primary_10_3389_fphar_2022_858693 crossref_primary_10_3390_ijerph192214714 crossref_primary_10_1093_infdis_jiad061 crossref_primary_10_3389_fimmu_2024_1330253 crossref_primary_10_1016_j_intimp_2023_110839 crossref_primary_10_1016_j_cell_2023_08_026 crossref_primary_10_3390_children10030419 crossref_primary_10_3389_fcvm_2023_1062491 crossref_primary_10_1186_s12911_024_02743_5 crossref_primary_10_1016_j_jccase_2023_02_016 crossref_primary_10_3390_v15020438 crossref_primary_10_3390_cancers16010096 crossref_primary_10_3390_vaccines10081306 crossref_primary_10_1016_j_medj_2022_07_003 crossref_primary_10_1016_j_scitotenv_2022_156724 crossref_primary_10_1371_journal_pmed_1003992 crossref_primary_10_1097_TP_0000000000004325 crossref_primary_10_1128_spectrum_04632_22 crossref_primary_10_1093_mmy_myae028 crossref_primary_10_1016_j_cmi_2025_07_029 crossref_primary_10_1016_j_intimp_2023_110460 crossref_primary_10_1001_jamanetworkopen_2023_1181 crossref_primary_10_3390_biomedicines11082113 crossref_primary_10_1016_j_lansea_2023_100348 crossref_primary_10_1007_s00590_023_03620_z crossref_primary_10_1016_S0140_6736_22_00514_1 crossref_primary_10_12968_bjon_2023_32_9_412 crossref_primary_10_3201_eid2910_230585 crossref_primary_10_1080_21645515_2024_2311969 crossref_primary_10_1093_ofid_ofac174 crossref_primary_10_1055_a_2235_0214 crossref_primary_10_3390_vaccines12020163 crossref_primary_10_3390_biomedicines11082103 crossref_primary_10_1016_j_jhep_2023_10_009 crossref_primary_10_1016_j_imu_2023_101256 crossref_primary_10_1186_s12985_025_02696_9 crossref_primary_10_3390_biomedicines11030901 crossref_primary_10_3389_fmed_2022_921135 crossref_primary_10_1186_s12879_024_09338_5 crossref_primary_10_3390_v15051129 crossref_primary_10_3390_ijms232214057 crossref_primary_10_1016_j_apm_2022_09_017 crossref_primary_10_1016_j_jhin_2023_04_014 crossref_primary_10_1002_cnr2_2103 crossref_primary_10_1186_s12967_023_04095_6 crossref_primary_10_1542_peds_2022_057564 crossref_primary_10_1016_j_celrep_2023_113292 crossref_primary_10_1097_HS9_0000000000000905 crossref_primary_10_3390_vaccines11010126 crossref_primary_10_1038_s41598_024_57238_0 crossref_primary_10_3390_jcm11216272 crossref_primary_10_59556_japi_72_0716 crossref_primary_10_1016_j_virol_2024_110050 crossref_primary_10_1016_j_cmi_2023_03_017 crossref_primary_10_1001_jamanetworkopen_2022_28900 crossref_primary_10_1016_S2213_2600_22_00222_3 crossref_primary_10_3390_ijerph192114318 crossref_primary_10_1111_imr_13089 crossref_primary_10_1111_imr_13086 crossref_primary_10_1186_s12879_023_08838_0 crossref_primary_10_1016_j_puhip_2024_100494 crossref_primary_10_2196_37377 crossref_primary_10_3390_vaccines11091502 crossref_primary_10_1093_ofid_ofad075 crossref_primary_10_1016_j_ajic_2022_09_007 crossref_primary_10_1016_j_isci_2024_110174 crossref_primary_10_1007_s43440_022_00424_6 crossref_primary_10_13105_wjma_v10_i3_177 crossref_primary_10_3390_v14061139 crossref_primary_10_1515_dx_2022_0084 crossref_primary_10_1136_bmjgh_2023_012245 crossref_primary_10_1016_j_heliyon_2024_e30724 crossref_primary_10_1186_s41100_023_00509_9 crossref_primary_10_1186_s12879_023_08771_2 crossref_primary_10_7326_M22_1745 crossref_primary_10_1016_j_jinf_2023_01_032 crossref_primary_10_3389_fimmu_2024_1408969 crossref_primary_10_1016_S2213_2600_24_00151_6 crossref_primary_10_1016_j_isci_2023_107735 crossref_primary_10_1111_bjh_18960 crossref_primary_10_1265_ehpm_23_00274 crossref_primary_10_3389_fimmu_2023_1100468 crossref_primary_10_3390_v15030618 crossref_primary_10_3390_vaccines11020379 crossref_primary_10_3390_v16081183 crossref_primary_10_3390_v15040886 crossref_primary_10_3390_jcm12041388 crossref_primary_10_1007_s00430_022_00752_7 crossref_primary_10_3389_fpubh_2022_876551 crossref_primary_10_1038_s41467_022_33740_9 crossref_primary_10_3389_fpubh_2022_1049006 crossref_primary_10_3389_fphar_2024_1362345 crossref_primary_10_3390_v14112519 crossref_primary_10_1016_j_jmii_2023_10_001 crossref_primary_10_1186_s12963_024_00330_4 crossref_primary_10_2196_42700 crossref_primary_10_1016_j_heliyon_2023_e15277 crossref_primary_10_3389_fpubh_2022_978052 crossref_primary_10_1016_j_ijregi_2024_100390 crossref_primary_10_1111_bjh_18700 crossref_primary_10_1016_j_ccm_2022_11_008 crossref_primary_10_5582_bst_2022_01526 crossref_primary_10_1186_s12879_022_07626_6 crossref_primary_10_1007_s11262_024_02067_6 crossref_primary_10_12998_wjcc_v11_i4_756 crossref_primary_10_3390_diagnostics12092245 crossref_primary_10_1007_s11845_022_03266_6 crossref_primary_10_1080_21505594_2025_2519141 crossref_primary_10_1038_s42003_024_07307_x crossref_primary_10_3201_eid2908_230071 crossref_primary_10_1055_s_0042_1756306 crossref_primary_10_2147_IDR_S389883 |
| Cites_doi | 10.1016/j.puhe.2021.03.012 10.1038/s41586-022-04474-x 10.1016/j.jinf.2021.08.039 10.1056/NEJMoa2119451 10.1016/S1473-3099(21)00475-8 10.1503/cmaj.211248 10.1016/S0140-6736(22)00017-4 10.1016/j.ijid.2021.12.357 10.1016/S0140-6736(21)01358-1 10.1016/S1473-3099(21)00580-6 10.2139/ssrn.3996320 10.1038/s41586-022-04479-6 10.2807/1560-7917.ES.2022.27.4.2200077 10.1016/S1473-3099(21)00290-5 |
| ContentType | Journal Article |
| Contributor | Volz, Erik Andrews, Nick Funk, Sebastian Ghani, Azra C Chand, Meera Lopez Bernal, Jamie Flaxman, Seth Presanis, Anne M Hinsley, Wes Seaman, Shaun R Blomquist, Paula Thelwall, Simon Zaidi, Asad Bhatt, Samir Nyberg, Tommy Charlett, Andre Ferguson, Neil M De Angelis, Daniela Nash, Sophie G Abdul Aziz, Nurin Webster, Harriet H Hope, Russell Harman, Katie Dabrera, Gavin Abbott, Sam Kall, Meaghan |
| Contributor_xml | – sequence: 1 givenname: Tommy surname: Nyberg fullname: Nyberg, Tommy – sequence: 2 givenname: Neil M surname: Ferguson fullname: Ferguson, Neil M – sequence: 3 givenname: Sophie G surname: Nash fullname: Nash, Sophie G – sequence: 4 givenname: Harriet H surname: Webster fullname: Webster, Harriet H – sequence: 5 givenname: Seth surname: Flaxman fullname: Flaxman, Seth – sequence: 6 givenname: Nick surname: Andrews fullname: Andrews, Nick – sequence: 7 givenname: Wes surname: Hinsley fullname: Hinsley, Wes – sequence: 8 givenname: Jamie surname: Lopez Bernal fullname: Lopez Bernal, Jamie – sequence: 9 givenname: Meaghan surname: Kall fullname: Kall, Meaghan – sequence: 10 givenname: Samir surname: Bhatt fullname: Bhatt, Samir – sequence: 11 givenname: Paula surname: Blomquist fullname: Blomquist, Paula – sequence: 12 givenname: Asad surname: Zaidi fullname: Zaidi, Asad – sequence: 13 givenname: Erik surname: Volz fullname: Volz, Erik – sequence: 14 givenname: Nurin surname: Abdul Aziz fullname: Abdul Aziz, Nurin – sequence: 15 givenname: Katie surname: Harman fullname: Harman, Katie – sequence: 16 givenname: Sebastian surname: Funk fullname: Funk, Sebastian – sequence: 17 givenname: Sam surname: Abbott fullname: Abbott, Sam – sequence: 18 givenname: Russell surname: Hope fullname: Hope, Russell – sequence: 19 givenname: Andre surname: Charlett fullname: Charlett, Andre – sequence: 20 givenname: Meera surname: Chand fullname: Chand, Meera – sequence: 21 givenname: Azra C surname: Ghani fullname: Ghani, Azra C – sequence: 22 givenname: Shaun R surname: Seaman fullname: Seaman, Shaun R – sequence: 23 givenname: Gavin surname: Dabrera fullname: Dabrera, Gavin – sequence: 24 givenname: Daniela surname: De Angelis fullname: De Angelis, Daniela – sequence: 25 givenname: Anne M surname: Presanis fullname: Presanis, Anne M – sequence: 26 givenname: Simon surname: Thelwall fullname: Thelwall, Simon |
| Copyright | 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. 2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2022 |
| Copyright_xml | – notice: 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: 2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2022 |
| CorporateAuthor | COVID-19 Genomics UK (COG-UK) consortium |
| CorporateAuthor_xml | – name: COVID-19 Genomics UK (COG-UK) consortium |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 5PM |
| DOI | 10.1016/S0140-6736(22)00462-7 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database (Proquest) Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1312 |
| ExternalDocumentID | PMC8926413 35305296 10_1016_S0140_6736_22_00462_7 S0140673622004627 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | England United Kingdom--UK |
| GeographicLocations_xml | – name: England – name: United Kingdom--UK |
| GrantInformation | Medical Research Council, UK Research and Innovation, Department of Health and Social Care, National Institute for Health Research, Community Jameel, and Engineering and Physical Sciences Research Council. |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_00002/10 – fundername: Medical Research Council grantid: MC_PC_19027 – fundername: Medical Research Council grantid: MC_PC_19074 – fundername: Medical Research Council grantid: MR/V038109/1 – fundername: Wellcome Trust – fundername: Medical Research Council grantid: MC_UU_00002/11 – fundername: Medical Research Council grantid: MC_PC_19012 – fundername: Medical Research Council grantid: MR/R015600/1 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD 6I. AACTN AAFTH AFCTW ALIPV M41 .GJ 04C 3EH 3O- 41~ 8WZ 9DU A6W AAEJM AAKAS AAQQT AAQXK AAYXX ABDBF ABWVN ACRPL ACUHS ADMUD ADNMO ADXHL ADZCM AFFHD AFFNX AGQPQ AHHHB AHQJS AJJEV AKVCP ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD Q~Q R2- SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 AGCQF AGRNS CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7TK 7U7 7U9 7XB 88A 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c549t-63454a5e85a42b177724cf6dd1229ce7f9f9e99d1f3160b0afbee2c3e343e3c63 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 943 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000812828300022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Tue Nov 04 01:58:58 EST 2025 Thu Oct 02 11:12:39 EDT 2025 Tue Oct 07 07:11:34 EDT 2025 Mon Jul 21 05:45:55 EDT 2025 Tue Nov 18 22:39:20 EST 2025 Sat Nov 29 07:22:52 EST 2025 Sun Apr 06 06:52:59 EDT 2025 Tue Oct 14 19:30:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10332 |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c549t-63454a5e85a42b177724cf6dd1229ce7f9f9e99d1f3160b0afbee2c3e343e3c63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Co-first authors Contributed equally |
| ORCID | 0000-0001-6268-8937 0000-0002-7717-6982 0000-0003-2838-6833 0000-0001-7154-0432 0000-0002-2145-8884 0000-0002-2842-3406 0000-0003-3726-5937 0000-0002-1301-5653 0000-0001-6619-6112 0000-0003-1387-0200 0000-0002-3962-4211 0000-0003-4606-5945 0000-0002-0007-4910 0000-0002-0891-4611 0000-0001-9697-0340 0000-0003-3078-4427 0000-0002-0434-2724 0000-0003-2069-2684 0000-0001-8057-8037 0000-0002-9436-0626 0000-0001-6971-427X 0000-0002-2477-4217 0000-0002-6420-2539 0000-0002-8098-6935 0000-0002-4597-1746 0000-0002-1154-8093 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8926413 |
| PMID | 35305296 |
| PQID | 2645814308 |
| PQPubID | 40246 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8926413 proquest_miscellaneous_2640995973 proquest_journals_2645814308 pubmed_primary_35305296 crossref_primary_10_1016_S0140_6736_22_00462_7 crossref_citationtrail_10_1016_S0140_6736_22_00462_7 elsevier_sciencedirect_doi_10_1016_S0140_6736_22_00462_7 elsevier_clinicalkey_doi_10_1016_S0140_6736_22_00462_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-02 |
| PublicationDateYYYYMMDD | 2022-04-02 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier |
| References | Wang, Berger, Kaelber, Davis, Volkow, Xu (bib12) 2022 Twohig, Nyberg, Zaidi (bib21) 2021; 22 Bager, Wohlfahrt, Fonager (bib38) 2021; 21 Meng, Abdullahi, Ferreira (bib30) 2022 (bib22) 2022 (bib25) Dec 8, 2021 (bib5) 2022 Veneti, Bøås, Bråthen Kristoffersen (bib13) 2022; 27 Wolter, Jassat, Walaza (bib6) 2022; 399 (bib26) Feb 15, 2022 bib28 Hui, Ho, Cheung (bib31) 2022 (bib1) Nov 26, 2021 Peralta-Santos, Rodrigues, Moreno (bib15) 2022 Clare, Twohig, O'Connell, Dabrera (bib20) 2021; 194 Davies, Kassanjee, Rosseau (bib17) 2022 Birrell, Blake, van Leeuwen, De Angelis (bib4) Dec 9, 2021 (bib19) 2022 (bib39) 2022 (bib23) 2022 Sheikh, McMenamin, Taylor, Robertson (bib34) 2021; 397 Bager, Wohlfahrt, Bhatt (bib11) 2022 Clark, Walker, Bennett, Herrick, Kenny, Gent (bib33) 2022 Vihta, Pouwels, Peto (bib32) 2022 Sheikh, Kerr, Woolhouse, McMenamin, Robertson (bib7) 2021 bib24 Lewnard, Hong, Patel, Kahn, Lipsitch, Tartof (bib10) 2022 Abdullah, Myers, Basu (bib14) 2022; 116 Bhattacharya, Collin, Stimson (bib27) 2021; 83 Seaman, Nyberg, Overton, Pascall, Presanis, De Angelis (bib29) 2021 Fisman, Tuite (bib36) 2021; 193 bib3 Bager, Wohlfahrt, Rasmussen, Albertsen, Krause (bib35) 2021; 21 Nyberg, Twohig, Harris (bib37) 2021; 373 Ulloa, Buchan, Daneman, Brown (bib9) 2022 Jassat, Abdool Karim, Mudara (bib16) 2021 bib2 Ferguson, Ghani, Hinsley, Volz (bib8) 2021 Andrews, Stowe, Kiresbom (bib18) 2022 Hui (10.1016/S0140-6736(22)00462-7_bib31) 2022 Lewnard (10.1016/S0140-6736(22)00462-7_bib10) 2022 Fisman (10.1016/S0140-6736(22)00462-7_bib36) 2021; 193 Vihta (10.1016/S0140-6736(22)00462-7_bib32) 2022 Twohig (10.1016/S0140-6736(22)00462-7_bib21) 2021; 22 Peralta-Santos (10.1016/S0140-6736(22)00462-7_bib15) 2022 Davies (10.1016/S0140-6736(22)00462-7_bib17) 2022 Sheikh (10.1016/S0140-6736(22)00462-7_bib7) 2021 Clare (10.1016/S0140-6736(22)00462-7_bib20) 2021; 194 Bhattacharya (10.1016/S0140-6736(22)00462-7_bib27) 2021; 83 Veneti (10.1016/S0140-6736(22)00462-7_bib13) 2022; 27 Clark (10.1016/S0140-6736(22)00462-7_bib33) 2022 Jassat (10.1016/S0140-6736(22)00462-7_bib16) 2021 Nyberg (10.1016/S0140-6736(22)00462-7_bib37) 2021; 373 Seaman (10.1016/S0140-6736(22)00462-7_bib29) 2021 Bager (10.1016/S0140-6736(22)00462-7_bib35) 2021; 21 Sheikh (10.1016/S0140-6736(22)00462-7_bib34) 2021; 397 Abdullah (10.1016/S0140-6736(22)00462-7_bib14) 2022; 116 Ferguson (10.1016/S0140-6736(22)00462-7_bib8) Birrell (10.1016/S0140-6736(22)00462-7_bib4) Bager (10.1016/S0140-6736(22)00462-7_bib38) 2021; 21 Ulloa (10.1016/S0140-6736(22)00462-7_bib9) 2022 Bager (10.1016/S0140-6736(22)00462-7_bib11) 2022 Wolter (10.1016/S0140-6736(22)00462-7_bib6) 2022; 399 Meng (10.1016/S0140-6736(22)00462-7_bib30) 2022 Wang (10.1016/S0140-6736(22)00462-7_bib12) 2022 Andrews (10.1016/S0140-6736(22)00462-7_bib18) 2022 36088948 - Lancet. 2022 Sep 10;400(10355):809. doi: 10.1016/S0140-6736(22)01469-6. 35305298 - Lancet. 2022 Apr 2;399(10332):1280-1281. doi: 10.1016/S0140-6736(22)00514-1. |
| References_xml | – volume: 21 start-page: 1507 year: 2021 end-page: 1517 ident: bib38 article-title: Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study publication-title: Lancet Infect Dis – ident: bib3 article-title: Tracking of variants – volume: 83 start-page: 565 year: 2021 end-page: 572 ident: bib27 article-title: Healthcare-associated COVID-19 in England: a national data linkage study publication-title: J Infect – year: 2022 ident: bib19 article-title: COVID-19 vaccine surveillance report: week 6 – volume: 27 year: 2022 ident: bib13 article-title: Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022 publication-title: Eurosurveillance – year: 2022 ident: bib22 article-title: SARS-CoV-2 variant data update, England: Version 21 – year: 2022 ident: bib18 article-title: Effectiveness of COVID-19 vaccines against the omicron (B.1.1.529) variant of concern publication-title: NEJM – year: 2021 ident: bib29 article-title: Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic publication-title: medRxiv – year: 2022 ident: bib10 article-title: Clinical outcomes among patients infected with omicron (B.1.1.529) SARS-CoV-2 variant in southern California publication-title: medRxiv – year: 2021 ident: bib8 article-title: Report 50: hospitalisation risk for omicron cases in England – year: 2022 ident: bib39 article-title: National influenza and COVID-19 surveillance report: 27 January 2022 (week 4) – volume: 21 year: 2021 ident: bib35 article-title: Hospitalisation associated with SARS-CoV-2 delta variant in Denmark publication-title: Lancet Infect Dis – volume: 193 start-page: e1619 year: 2021 end-page: e1625 ident: bib36 article-title: Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada publication-title: CMAJ – year: 2022 ident: bib32 article-title: Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom publication-title: medRxiv – volume: 399 start-page: 437 year: 2022 end-page: 446 ident: bib6 article-title: Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study publication-title: Lancet – year: 2022 ident: bib17 article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa publication-title: medRxiv – year: Feb 15, 2022 ident: bib26 article-title: Secondary uses service (SUS) – year: Nov 26, 2021 ident: bib1 article-title: Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern – year: 2022 ident: bib11 article-title: Reduced risk of hospitalisation associated with infection with SARS-CoV-2 omicron relative to delta: a Danish cohort study publication-title: SSRN – year: 2022 ident: bib12 article-title: COVID infection severity in children under 5 years old before and after omicron emergence in the US publication-title: medRxiv – ident: bib24 article-title: National Vaccination Programmes – year: 2022 ident: bib5 article-title: SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 35 – volume: 116 start-page: 38 year: 2022 end-page: 42 ident: bib14 article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa publication-title: Int J Infect Dis – volume: 194 start-page: 163 year: 2021 end-page: 166 ident: bib20 article-title: Timeliness and completeness of laboratory-based surveillance of COVID-19 cases in England publication-title: Public Health – volume: 373 year: 2021 ident: bib37 article-title: Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis publication-title: BMJ – ident: bib28 article-title: COVID-19 hospital activity – volume: 397 start-page: 2461 year: 2021 end-page: 2462 ident: bib34 article-title: SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness publication-title: Lancet – year: 2022 ident: bib31 article-title: SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo publication-title: Nature – year: 2022 ident: bib33 article-title: Clinical characteristics of SARS-CoV-2 omicron infection in children under one year publication-title: SSRN – year: 2021 ident: bib7 article-title: Severity of omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland – year: 2022 ident: bib9 article-title: Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada publication-title: JAMA – year: Dec 8, 2021 ident: bib25 article-title: Emergency care data set (ECDS) – year: 2021 ident: bib16 article-title: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the omicron-dominant fourth wave publication-title: SSRN – year: Dec 9, 2021 ident: bib4 article-title: Report on nowcasting and forecasting – volume: 22 start-page: 35 year: 2021 end-page: 42 ident: bib21 article-title: Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1·1.7) variants of concern: a cohort study publication-title: Lancet Infect Dis – year: 2022 ident: bib23 article-title: NHS Test and Trace statistics (England): methodology – year: 2022 ident: bib15 article-title: Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with delta (B.1.617.2) publication-title: medRxiv – year: 2022 ident: bib30 article-title: Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts tropism and fusogenicity publication-title: Nature – ident: bib2 article-title: Science brief: omicron (B.1.1.529) variant – year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib7 – volume: 194 start-page: 163 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib20 article-title: Timeliness and completeness of laboratory-based surveillance of COVID-19 cases in England publication-title: Public Health doi: 10.1016/j.puhe.2021.03.012 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib30 article-title: Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts tropism and fusogenicity publication-title: Nature doi: 10.1038/s41586-022-04474-x – volume: 83 start-page: 565 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib27 article-title: Healthcare-associated COVID-19 in England: a national data linkage study publication-title: J Infect doi: 10.1016/j.jinf.2021.08.039 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib33 article-title: Clinical characteristics of SARS-CoV-2 omicron infection in children under one year publication-title: SSRN – volume: 373 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib37 article-title: Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis publication-title: BMJ – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib18 article-title: Effectiveness of COVID-19 vaccines against the omicron (B.1.1.529) variant of concern publication-title: NEJM doi: 10.1056/NEJMoa2119451 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib11 article-title: Reduced risk of hospitalisation associated with infection with SARS-CoV-2 omicron relative to delta: a Danish cohort study publication-title: SSRN – ident: 10.1016/S0140-6736(22)00462-7_bib4 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib12 article-title: COVID infection severity in children under 5 years old before and after omicron emergence in the US publication-title: medRxiv – year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib29 article-title: Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic publication-title: medRxiv – volume: 22 start-page: 35 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib21 article-title: Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1·1.7) variants of concern: a cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00475-8 – volume: 193 start-page: e1619 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib36 article-title: Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada publication-title: CMAJ doi: 10.1503/cmaj.211248 – volume: 399 start-page: 437 year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib6 article-title: Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study publication-title: Lancet doi: 10.1016/S0140-6736(22)00017-4 – volume: 116 start-page: 38 year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib14 article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.12.357 – volume: 397 start-page: 2461 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib34 article-title: SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness publication-title: Lancet doi: 10.1016/S0140-6736(21)01358-1 – volume: 21 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib35 article-title: Hospitalisation associated with SARS-CoV-2 delta variant in Denmark publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00580-6 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib10 article-title: Clinical outcomes among patients infected with omicron (B.1.1.529) SARS-CoV-2 variant in southern California publication-title: medRxiv – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib9 article-title: Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada publication-title: JAMA – year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib16 article-title: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the omicron-dominant fourth wave publication-title: SSRN doi: 10.2139/ssrn.3996320 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib31 article-title: SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo publication-title: Nature doi: 10.1038/s41586-022-04479-6 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib32 article-title: Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom publication-title: medRxiv – volume: 27 year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib13 article-title: Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2022.27.4.2200077 – ident: 10.1016/S0140-6736(22)00462-7_bib8 – volume: 21 start-page: 1507 year: 2021 ident: 10.1016/S0140-6736(22)00462-7_bib38 article-title: Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00290-5 – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib15 article-title: Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with delta (B.1.617.2) publication-title: medRxiv – year: 2022 ident: 10.1016/S0140-6736(22)00462-7_bib17 article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa publication-title: medRxiv – reference: 35305298 - Lancet. 2022 Apr 2;399(10332):1280-1281. doi: 10.1016/S0140-6736(22)00514-1. – reference: 36088948 - Lancet. 2022 Sep 10;400(10355):809. doi: 10.1016/S0140-6736(22)01469-6. |
| SSID | ssj0004605 |
| Score | 2.7526066 |
| Snippet | The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity... Summary Background The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1303 |
| SubjectTerms | Age Age groups Cohort analysis Cohort Studies Comparative analysis Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines Death Deprivation Emergency medical care England - epidemiology Estimates Hospitalization Humans Infections Intensive care Medical research Mortality mRNA mRNA Vaccines Patient admissions Physical sciences Reduction Risk SARS-CoV-2 Secondary analysis Severe acute respiratory syndrome coronavirus 2 Testing laboratories Vaccine efficacy Vaccines Vaccines, Synthetic |
| Title | Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673622004627 https://dx.doi.org/10.1016/S0140-6736(22)00462-7 https://www.ncbi.nlm.nih.gov/pubmed/35305296 https://www.proquest.com/docview/2645814308 https://www.proquest.com/docview/2640995973 https://pubmed.ncbi.nlm.nih.gov/PMC8926413 |
| Volume | 399 |
| WOSCitedRecordID | wos000812828300022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwELbYhhAv4zcLjMpIPKwP6RLbiW1e0FZt4qWlasfUt8h1HK3SlIw227_Ev4nPcVIGgyGhKCcl8VWNcro72999h9CHXPEolQSgOjoKGV8Y6wc1VHIpI4SWecwWrtkEH4_FfC4nfsFt7WGVrU90jjqvNKyRH9rAnQgb3CPx6epbCF2jYHfVt9DYQjvAkkAddG9yV12kg7hvKngOZ93NA0L6rkQz5H-KTb_nnr9CKH-KSadP_vdtnqJdn43io8Z8nqEHpnyOHo38fvsL9H24IQfHyvOX4KrANm3EgEp3Fxe-94hHBtmBOc4htcTKf3yTY1jwxbOj6SwcVuchwVANvbKDD44HsT0SIvte8bJWzV2b9gxIH9_Y6TygdfCyxL7nyEesMLT2XdXY8eO-RF9PT86Gn0Pf2iHUdkJahyllCVOJEYliBBiwOGG6SPM8JkRqwwtZSCOtpRQ0TqNFpIqFMURTQ5k9dUpfoe2yKs0ewiSnsNUbkULBXJdLxbQB2jbNRMEZCxBrP2qmPe85tN-4zO4AuBGSOVvIeIAGndpVQ_xxn0LaWkzWVrVaP5zZ0HSfougUfdrTpDP_orrfmlfmfc8629hWgN53j63XgK0gVZrq2o2JgGmO0wC9biy5e0uaUNj-TQPEb9l4NwAYyW8_KZcXjplcSPvDMX3z97_1Fj0mUEQC-Ceyj7br1bV5hx7qm3q5XvXQFp-eg5xzJ4WVYhj30M7xyXgytVejqJFnIMnIyS9OTnrOAfwAIqxQSA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoALb9qFAkYCqXvINrGdOEZCqCxUrdpdIXZBvQWv46grVUnZTYv4Rdz4jXgSJ0uhUC49oCiHJB4rj_HMOP7mG4BnqRJ-JClCdbTvcTEx1g5qzORSJo61TAM-qYpNiOEw3t-X75bge5MLg7DKxiZWhjotNP4j37COO4ytc_fjV0efPawahaurTQmNWi12zdcvdso2f7nzxn7f55RuvR33tz1XVcDTdi5UehHjIVehiUPFKZIvCcp1FqVpQKnURmQyk0bam8xYEPkTX2UTY6hmhnG764jZfi_BZeTVQwjhwB-flYdZQeoXGUMbo_bkOqXdKiXUE3_yhb_Hur9CNn_ygVs3_7e3dwtuuGibbNbD4zYsmfwOXB04PMFd-NZfkJ8T5fhZSJERGxYTRN1XBweutopDPtmGKUkxdCbKKbdJCf7QJqPN9yOvX3z0KMFs75ltvP66F9gtpLLrBA9LVZ-1YV2PdsmJskYgL-dkmhNXU-UFUQRLF89KUvH_3oMPF_Ka7sNyXuRmFQhNGS5l-zRTOJcXUnFtkJZO8zgTnHeAN0qUaMfrjuVFDpMzAHyUJpXuJaIDvVbsqCY2OU8gajQ0abJ2rZ9JrOs9TzBuBV1YV4dr_yK61qhz4mzrPFnocgeetpetVcSlLpWb4rhq4yOTnmAdWKlHTvuULGS4vB11QJwaU20DZFw_fSWfHlTM67G0HQfswd9v6wlc2x4P9pK9neHuQ7hOMWEGsV50DZbL2bF5BFf0STmdzx5X5oPAp4secT8ArySjuQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgiouvB-BAosEUnNwYu-uvTYSQiUloipEFQHUm9ms12qkyimJW8Qv4j_w65ix1w6FQrn0gCIfYu9Yfsxrvd98A_Ak08qPEk5QHeN7Uk0s-kFDlVzaxrFJskBOqmYTajSK9_aS3RX43tTCEKyy8YmVo85mhr6R9zFwhzEGdz_u5w4Wsbs1fHH42aMOUrTS2rTTqFVkx379gtO3xfPtLXzXTzkfvno_eO25DgOewXlR6UVChlKHNg615ETEpLg0eZRlAeeJsSpP8sQmeMG5CCJ_4ut8Yi03wgqJm4kEnvcCXFQCtZiq1AfBaTWZFbx-WT3UH7c7NzjvVuWhnvpTXPw97_0VvvlTPBxe_Z-f5DW44rJwtlmbzXVYscUNWHvrcAY34dtgSYrOtONtYbOcYbrMCI1f_dl3PVccIgoHZiyjlJppp_Q2Y_Shm4033429weyjxxlVgc9x8MbLXoC_kCddJ3hQ6novpns93mXHGp1DUS7YtGCu18ozphm1NJ6XrOIFvgUfzuUx3YbVYlbYu8B4JmiJ2-e5pjm-SrQ0lujqjIxzJWUHZKNQqXF879R25CA9BdjHeVrpYao60GvFDmvCk7MEokZb06aaF-NPiiH5LMG4FXTpXp3G_YvoeqPaqfO5i3Sp1x143B5Gb0lLYLqws6NqjE8Me0p04E5tRe1dilDQsnfUAXXCvtoBxMR-8kgx3a8Y2eMETxyIe3-_rEewhoaWvtke7dyHy5zqaAgCxtdhtZwf2QdwyRyX08X8YeVJGHw6b4P7ATCYrDc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+analysis+of+the+risks+of+hospitalisation+and+death+associated+with+SARS-CoV-2+omicron+%28B.1.1.529%29+and+delta+%28B.1.617.2%29+variants+in+England%3A+a+cohort+study&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Nyberg%2C+Tommy&rft.au=Ferguson%2C+Neil+M&rft.au=Nash%2C+Sophie+G&rft.au=Webster%2C+Harriet+H&rft.date=2022-04-02&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.volume=399&rft.issue=10332&rft.spage=1303&rft.epage=1312&rft_id=info:doi/10.1016%2FS0140-6736%2822%2900462-7&rft.externalDocID=S0140673622004627 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |